Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 29, 2025 06:00 ET | Source: Adlai Nortye Ltd.

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
December 28, 2025 19:00 ET | Source: Transcenta

Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics

PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with...
December 28, 2025 16:45 ET | Source: Weebit Nano Ltd

Weebit Nano secures a license agreement with Texas Instruments

TI has licensed Weebit ReRAM. The advanced NVM IP will be integrated into TI’s advanced process nodes for embedded processing semiconductors.
December 22, 2025 09:43 ET | Source: MiMedx Group, Inc

MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel

MARIETTA, Ga., Dec. 22, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it has entered into an exclusive agreement with Regen Lab USA LLC to...
December 22, 2025 08:05 ET | Source: Adeia Inc.

Adeia and Disney Enter Into Long-Term Media IP License Agreement

ADEIA AND DISNEY ENTER INTO LONG-TERM MEDIA IP LICENSE AGREEMENT
December 21, 2025 19:26 ET | Source: Windward Bio

Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13

Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatologyWIN027 blocks...
December 18, 2025 07:02 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...
December 17, 2025 07:00 ET | Source: Sagimet Biosciences Inc.

Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program

License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent...
December 15, 2025 16:51 ET | Source: Cellectis Inc.

Cellectis annonce la décision du tribunal arbitral dans le litige l’opposant à Servier

NEW YORK, 15 déc. 2025 (GLOBE NEWSWIRE) -- Cellectis (la « Société ») (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière...
December 15, 2025 16:51 ET | Source: Cellectis Inc.

Cellectis Announces Arbitral Decision in Dispute with Servier

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...